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ABSTRACT
Objectives To approximate the rate of familial myasthenia 
gravis and the coexistence of other autoimmune disorders 
in the patients and their families.
Design Retrospective cohort study.
Setting Clinics across North America.
Participants The study included 1032 patients diagnosed 
with acetylcholine receptor antibody (AChR)- positive 
myasthenia gravis.
Methods Phenotype information of 1032 patients 
diagnosed with AChR- positive myasthenia gravis was 
obtained from clinics at 14 centres across North America 
between January 2010 and January 2011. A critical review 
of the epidemiological literature on the familial rate of 
myasthenia gravis was also performed.
Results Among 1032 patients, 58 (5.6%) reported 
a family history of myasthenia gravis. A history of 
autoimmune diseases was present in 26.6% of patients 
and in 28.4% of their family members.
Discussion The familial rate of myasthenia gravis was 
higher than would be expected for a sporadic disease. 
Furthermore, a high proportion of patients had a personal 
or family history of autoimmune disease. Taken together, 
these findings suggest a genetic contribution to the 
pathogenesis of myasthenia gravis.
INTRODUCTION
Myasthenia gravis is a rare autoimmune 
disease that is characterised by antibody- 
mediated interference with neuromuscular 
transmission at the neuromuscular junction. 
Originally, the role for an autoimmune attack 
against the acetylcholine receptor (AChR) on 
the postsynaptic side of the neuromuscular 
junction was recognised.1 However, over the 
past decade, additional autoimmune targets 
have been identified: muscle- specific tyro-
sine kinase (MuSK), agrin and lipoprotein 
receptor- related protein 4 (LRP4).2–4 All of 
these proteins play essential roles in main-
taining the structure and function of the 
neuromuscular junction.
Myasthenia gravis manifests clinically with 
muscle weakness and fatigability. Symptoms 
of ocular muscle weakness are observed early 
Strengths and limitations of this study
 ► A strength of this study is that it analyses a large 
cohort of patients with myasthenia gravis with com-
plete data on each patient, allowing multiple clinical 
correlations to be made.
 ► A strength of this study is that standardised crite-
ria were used to diagnose patients with myasthenia 
gravis, including establishing the specific subtype of 
the disease for each patient.
 ► A strength of this study is that the cohort of patients 
with myasthenia gravis was sufficiently large to al-
low the generation of evidence confirming a genetic 
contribution to the disease.
 ► A limitation of this study is the reliance on self- 
reported family history status for both myasthe-
nia gravis and other autoimmune diseases by the 
patients.
 ► A limitation of this study is its retrospective design, 
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in 85% of patients with myasthenia gravis.5 These symp-
toms include diplopia and/or ptosis. Weakness of the 
bulbar musculature is observed in 60% of patients with 
myasthenia gravis, with symptoms including dysarthria 
and/or dysphagia.5
A recent literature review of 31 epidemiological studies 
suggests that the annual incidence of myasthenia gravis 
may range between 3 and 30 cases per million people.6 
A common theme among myasthenia gravis epidemio-
logical studies is that there is a significant degree of vari-
ability between cohorts. For example, a study of a Hong 
Kong Chinese cohort reported an incidence of 4 per 
million people per year, whereas a study of an English 
cohort reported an incidence of 30 per million people 
per year.7 8 This substantial degree of variability may be 
the result of inconsistent diagnostic criteria, varying case 
ascertainment, lack of physician awareness concerning 
myasthenia gravis or it may reflect different occurrence 
across populations.
Historically, adult- onset myasthenia gravis has been 
regarded as a sporadic disease with only a minimal 
genetic component.9 However, genome- wide associa-
tion studies, fine- mapping studies and epidemiological 
studies of myasthenia gravis suggest a genetic contribu-
tion to the disease.10 11 In fact, studies have described 
patients with myasthenia gravis that have a family history 
of myasthenia gravis and/or a family history of autoim-
mune diseases.12–16 In this study, we performed a litera-
ture search of the familial rate reported by myasthenia 
gravis epidemiological studies and, using our cohort of 
1032 North American patients with myasthenia gravis, 
approximated the prevalence of familial myasthenia 
gravis, compared the characteristics of familial disease 
with sporadic disease and assessed the comorbidity of 




Phenotype information of 1032 patients diagnosed with 
myasthenia gravis was obtained from myasthenia gravis 
clinics at 14 centres across North America between January 
2010 and January 2011.10 The numbers of patients with 
myasthenia gravis attending each of these clinics were not 
available for this study. Patients were diagnosed by neurol-
ogists specialising in myasthenia gravis. Each myasthenia 
gravis diagnosis was based on standard clinical criteria 
that included, but was not limited to, weakness, fatigability 
and electrophysiological, pharmacological (edropho-
nium test) and/or serological abnormalities. Inclusion 
criteria for this study were as follows: confirmed diag-
nosis of myasthenia gravis, non- Hispanic white ethnicity 
and the presence of anti- AChR antibodies. Patients with 
anti- MuSK antibodies were excluded from the study. The 
LRP4 antibody was discovered after the collection of the 
cohort was complete. Thus, the LRP4 antibody status of 
the patients was not known. Family histories of myasthenia 
gravis and other autoimmune diseases were systematically 
obtained for each subject using a simple structured ques-
tionnaire (see online supplementary table S1). A positive 
family history was defined as having a first- degree (~50% 
of DNA in common), second- degree (~25% of DNA in 
common) or third- degree (~12.5% of DNA in common) 
relative with the disease. DNA samples were collected 
from each subject and used for genetic analyses as previ-
ously reported.10 Patients with genetic forms of myas-
thenia gravis were not explicitly excluded, though none 
in the cohort was known to have such a mutation.
Literature review methodology
To find studies about the epidemiology of familial myas-
thenia gravis, the PubMed and Medline databases were 
searched using permutations of search terms: ‘epidemi-
ology of familial myasthenia gravis’, ‘epidemiology of 
myasthenia gravis’ and ‘heritability of myasthenia gravis’. 
After reviewing 31 epidemiological studies between the 
years of 1950 through 2018, only 10 studies explicitly 
referenced a family history of myasthenia gravis. Five of 
those papers provided metrics about family members 
with myasthenia gravis.12–16
Patient and public involvement statement
No patients or members of the public were actively 
involved with co- producing the research presented in this 
article.
RESULTS
North American cohort of patients with myasthenia gravis
Clinical data were collected from a total of 1032 patients 
across 14 centres in North America and were analysed 
in this study. All of the patients had positive anti- AChR 
antibodies. The median age of symptom onset in this 
clinic- based cohort was 58 years of age (range=4–91; 
median onset age for females=46; median onset age for 
males=62). The female- to- male ratio was 1:1.27. Early- 
onset disease (<40 years of age) was observed among 248 
(24.0%) of the cohort. Consistent with other reports, 
nearly one- third of the patients in our North American 
study cohort (305, 29.6%) had undergone thymectomy.
Fifty- eight (5.6%) patients had a family history of myas-
thenia gravis. Sibling–sibling (31.0%) and parent–child 
(32.8%) were the most common types of familial relation-
ship, followed by uncle/aunt–nephew/niece (13.8%), 
cousin–cousin (12.1%) and grandparent–grandchild 
(5.2%) relationships. Of note, the indicated percentage 
of parent–child cases might be inflated because neonatal 
myasthenia gravis cases (which are not believed to be 
genetic) could not be discerned from non- neonatal cases. 
Age at symptom onset was similar among patients with 
a family history compared with patients without a family 
history (57.5 years of age, range=8–80 years vs 58.5 years, 
range=4–91 years, p value=0.183, Wilcoxon rank- sum test, 

















pen: first published as 10.1136/bm






3Green JD, et al. BMJ Open 2020;10:e037909. doi:10.1136/bmjopen-2020-037909
Open access
A personal history of an autoimmune disease other 
than myasthenia gravis was reported in 275 (26.6%) of 
study participants. A total of 293 (28.4%) subjects had 
a family history of an autoimmune disease. The preva-
lence of autoimmune disease in the general population 
is ~3%–9%, indicating that the rates observed among our 
myasthenia gravis subjects are significantly increased.17 A 
breakdown of the specific autoimmune diseases for both 
personal history and family history of disease is shown in 
figure 2A,B.
The most common autoimmune diseases present 
concomitantly in patients with myasthenia gravis were 
thyroid disease (n=118, 11.4%), haematological disease 
(n=33, 3.2% consisting of autoimmune haemolytic 
anaemia and autoimmune thrombocytopenic purpura) 
and rheumatoid arthritis (n=28, 2.7%). This was similar 
to the rates previously reported by Mao et al (figure 2C).18
The three most common autoimmune diseases present 
in the families of patients with myasthenia gravis were 
thyroid disease (n=98, 9.5%), rheumatoid arthritis (n=68, 
6.6%) and type 1 diabetes (n=36, 3.5%).
Literature review
Literature review concerning the epidemiology of familial 
myasthenia gravis identified five studies that discussed 
the patient’s family history of myasthenia gravis with 
sample sizes that ranged from 264 to 6638 (table 2).12–16 
The frequency of familial myasthenia gravis ranged from 
0.2% to 7.2% across studies, the upper limit having been 
reported for a Finnish cohort.15 Among these, three 
studies reported that familial myasthenia gravis cases 
had an earlier symptom onset age than the sporadic 
cases.12 14 15 Only three studies reported on the patient 
history of other autoimmune diseases and/or on the 
family history of other autoimmune diseases.12 14 15 Among 
these, thyroid disease, rheumatoid arthritis, systemic 
lupus erythematosus and Sjogren’s syndrome were the 
most common other autoimmune diseases reported in 
patients’ personal and/or family histories.12 14 15
DISCUSSION
We found the prevalence of familial myasthenia gravis 
in our North American cohort to be 5.6%. Our previous 
genetic analysis of this cohort showed the heritability 
of myasthenia gravis to be 25.5%.10 This is comparable 
to the prevalence reported in other studies, where the 
frequency ranged from 0.2% to 7.2% of patients with 
myasthenia gravis having a family history of myasthenia 
gravis depending on the cohort studied.12–16 Although 
the vast majority of myasthenia gravis cases are still 
non- familial, a prevalence of 5.6% represents a several 
hundred- fold increase for a disease with an overall prev-
alence of 1 in 5–10 000.5 The two studies of myasthenia 
gravis based on Asian cohorts reported substantially lower 
rates of familial disease compared with our North Amer-
ican cohort and other European cohorts. For example, 
two studies of Taiwanese (n=6638) and Japanese (n=3141) 
cohorts reported rates of familial myasthenia gravis at 
0.2% and 0.7%, respectively.12 13 Three studies of Spanish, 
American, and Finnish cohorts reported rates of 3.5%, 
3.8% and 7.2% (table 2).14–16 The familial rate reported 
in our cohort of over 1000 patients were, as expected, 
closer in value to the rates reported among European and 
American cohorts. Overall, these data suggest that there 
is population variation in the inheritance of myasthenia 
gravis that warrants further study to identify the genetic 
contribution to disease risk.
A notable feature of our cohort is that males had a 
slightly higher prevalence of familial myasthenia gravis 
compared with females (1:1.32), suggesting that there 
might be sex- specific differences in the occurrence of 
familial versus sporadic disease. This observation may 
Figure 1 Symptom- onset age distribution of sporadic and 
familial cases. The density represents the relative probability 
of myasthenia gravis at each age point.
Table 1 Comparison of familial and sporadic cases among 
a cohort of patients diagnosed with myasthenia gravis 
(n=1032)




58 (5.6) 974 (94.4) –
Median age of 
disease onset 
(years) (range)






15 (25.9) 233 (23.9) 0.86
Number of 
females (%)
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reflect the different age distribution of myasthenia gravis 
cases in males versus females observed across all myas-
thenia gravis cases. The reason for this is unclear, though 
we note that our previous genome- wide association study 
of myasthenia gravis indicated that the genetic architec-
ture was different among younger and older age groups.10
Myasthenia gravis is an immunological disorder and, 
generally speaking, autoimmune diseases are known to 
have heritable components.19 Likewise, approximately 
one- third of our cohort had a personal history and/or a 
family history of another autoimmune disease, which is 
much higher than the prevalence of 3%–9%, which has 
been historically reported in the general population.17 
We found that 19% (11/58) of the familial myasthenia 
gravis cases also had a personal history of autoimmune 
diseases; this was more than the sporadic myasthenia 
gravis cases in which only 10% (98/974) had a personal 
history of autoimmune diseases. Similar to previous 
reports, we found thyroid disease, rheumatoid arthritis, 
systemic lupus erythematosus and type 1 diabetes 
to be the most commonly identified comorbidities 
(figure 2C).18 19 Interestingly, the frequency of thyroid 
disease in this cohort (11.4%) is similar to the frequency 
range of thyroid disease reported in a study by Kiessling 
et al.20 The increased prevalence of familial myasthenia 
gravis and increased prevalence of other autoimmune 
disorders both suggest that these autoimmune diseases 
may share a common predisposition that may be genetic 
in origin. We speculate that the link between thyroid 
disease and myasthenia gravis may be due to a common 
genetic background or an immunological cross- reactivity 
against epitopes or auto- antigens shared by the thyroid 
and other tissues relevant to myasthenia gravis.21 22 Future 
Figure 2 Autoimmune diseases in a cohort of 1032 patients with myasthenia gravis. (A) Occurrence of autoimmune diseases 
among patients with myasthenia gravis (n=275). (B) Occurrence of autoimmune diseases among familial relatives of patients 
with myasthenia gravis (n=293). (C) Comparisons of autoimmune diseases among patients with myasthenia gravis and among 
relatives. Size of each circle represents the percentage previously reported by Mao et al.18






rate (%) Study type
12 Taiwan 6638 0.2 Population
13 Japan 3141 0.7 Population
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studies focusing on specific genes and genomic variants 
encountered in patients with familial myasthenia gravis 
offer the promise to more precisely identify any genetic 
contributions to the disease.
While our study has some notable strengths, it also 
has an inherent limitation related to its reliance on self- 
reported family histories, which could have overesti-
mated or underestimated the prevalence of the diseases 
studied. For example, it is plausible that a patient could 
self- report as not having a family history of myasthenia 
gravis because a family member was never clinically diag-
nosed with the disease or did not live long enough for the 
disease to manifest. Similarly, other studies have found 
an overestimation of some autoimmune diseases, espe-
cially thyroid disease and rheumatoid arthritis, related to 
self- reporting.23
Our analyses provide evidence of a genetic contribution 
to myasthenia gravis based on the higher than expected 
rate of familial disease observed among our North Amer-
ican patient cohort as well as the co- occurrence of auto-
immune diseases known to have a genetic basis among 
this population. More work needs to be done to further 
elucidate the genetic aetiology of this archetypal autoim-
mune disease.
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